{"disease":{"id":"nasopharyngeal-carcinoma-npc","name":"nasopharyngeal carcinoma npc"},"drugs":{"marketed":[{"drug_id":"toripalimab","indication_name":"metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Loqtorzi","generic_name":"TORIPALIMAB","company_name":"Coherus Biosciences Inc","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Loqtorzi blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06870435","title":"Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas","phase":"NA","overall_status":"RECRUITING","enrollment_count":68649,"lead_sponsor_name":"Ming-Yuan Chen","has_results":false},{"nct_id":"NCT07072143","title":"An International Study on Pediatric Patients With Rare Tumors.","phase":"","overall_status":"RECRUITING","enrollment_count":6250,"lead_sponsor_name":"Azienda Ospedaliera di Padova","has_results":false},{"nct_id":"NCT07088861","title":"Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1401,"lead_sponsor_name":"Lirong Wu","has_results":false},{"nct_id":"NCT07137052","title":"Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":732,"lead_sponsor_name":"The First Affiliated Hospital of Xiamen University","has_results":false},{"nct_id":"NCT06763289","title":"Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: CfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection","phase":"","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"First Affiliated Hospital, Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06900218","title":"PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":664,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06712888","title":"Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":466,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07328841","title":"Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":456,"lead_sponsor_name":"Ming-Yuan Chen","has_results":false},{"nct_id":"NCT03973723","title":"Plasma EBV DNA Monitoring in Post-treatment NPC Patients","phase":"","overall_status":"COMPLETED","enrollment_count":441,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT06695936","title":"Treatment with Intensity Modulated Radiotherapy on the Change of Cognitive Function in Nasopharyngeal Carcinoma Patients: a Prospective Cohort Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":329,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07340515","title":"Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Man Hu","has_results":false},{"nct_id":"NCT07459296","title":"Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":266,"lead_sponsor_name":"First Affiliated Hospital of Guangxi Medical University","has_results":false},{"nct_id":"NCT06612697","title":"Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":262,"lead_sponsor_name":"Taichung Veterans General Hospital","has_results":false},{"nct_id":"NCT07303283","title":"Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":218,"lead_sponsor_name":"Kai Hu","has_results":false},{"nct_id":"NCT06763640","title":"Prognostic Value of TIL in Nasopharyngeal Carcinoma","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":216,"lead_sponsor_name":"Jiangxi Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT04215978","title":"Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT07327216","title":"Sapylin Versus Dexamethasone Inhalation for CCRT-Induced Oral Mucositis in Nasopharyngeal Carcinoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Affiliated Hospital of Guangdong Medical University","has_results":false},{"nct_id":"NCT07188584","title":"Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":166,"lead_sponsor_name":"Ming-Yuan Chen","has_results":false},{"nct_id":"NCT07085988","title":"Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":109,"lead_sponsor_name":"Jiangxi Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT06839066","title":"A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Shanghai Henlius Biotech","has_results":false},{"nct_id":"NCT06987123","title":"TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":62,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07011329","title":"Brain Alterations Based on Multiplex MR Imaging in Nasopharyngeal Carcinoma Patients After Treatment, and Their Correlation With Clinical Cognitive Scores.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Hubei Cancer Hospital","has_results":false},{"nct_id":"NCT07064902","title":"Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07101744","title":"Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07252375","title":"A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT07136519","title":"Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Affiliated Hospital of Guangdong Medical University","has_results":false},{"nct_id":"NCT06796270","title":"Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"The Second Affiliated Hospital of Hainan Medical University","has_results":false},{"nct_id":"NCT06611150","title":"Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07277764","title":"Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":23,"lead_sponsor_name":"Jiangxi Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT03769467","title":"Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Atara Biotherapeutics","has_results":true},{"nct_id":"NCT06752473","title":"KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial","phase":"EARLY_PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Kousai Bio Co., Ltd.","has_results":false},{"nct_id":"NCT06676293","title":"Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT02822495","title":"Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false}],"total":33},"guidelines":[],"source":"Drug Landscape verified database"}